HomeCompareMURA vs EQR

MURA vs EQR: Dividend Comparison 2026

MURA yields 98.04% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MURA wins by $3.55M in total portfolio value
10 years
MURA
MURA
● Live price
98.04%
Share price
$2.04
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3.59M
Annual income
$1,195,548.96
Full MURA calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — MURA vs EQR

📍 MURA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMURAEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MURA + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MURA pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MURA
Annual income on $10K today (after 15% tax)
$8,333.33/yr
After 10yr DRIP, annual income (after tax)
$1,016,216.62/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, MURA beats the other by $1,011,562.35/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MURA + EQR for your $10,000?

MURA: 50%EQR: 50%
100% EQR50/50100% MURA
Portfolio after 10yr
$1.82M
Annual income
$600,512.28/yr
Blended yield
32.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

MURA
Analyst Ratings
1
Buy
1
Hold
Consensus: Buy
Altman Z
-8.4
Piotroski
1/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MURA buys
0
EQR buys
0
No recent congressional trades found for MURA or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMURAEQR
Forward yield98.04%5.87%
Annual dividend / share$2.00$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$3.59M$47.8K
Annual income after 10y$1,195,548.96$5,475.61
Total dividends collected$3.20M$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: MURA vs EQR ($10,000, DRIP)

YearMURA PortfolioMURA Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$20,504$9,803.92$11,380$679.82+$9.1KMURA
2$40,726$18,786.81$13,014$837.25+$27.7KMURA
3$78,451$34,874.18$14,961$1,036.20+$63.5KMURA
4$146,726$62,783.72$17,297$1,289.22+$129.4KMURA
5$266,739$109,741.95$20,121$1,613.15+$246.6KMURA
6$471,863$186,452.24$23,561$2,030.84+$448.3KMURA
7$813,151$308,257.14$27,783$2,573.54+$785.4KMURA
8$1,366,531$496,460.13$33,013$3,284.39+$1.33MMURA
9$2,241,927$779,738.88$39,547$4,223.51+$2.20MMURA
10$3,594,411$1,195,548.96$47,791$5,475.61+$3.55MMURA

MURA vs EQR: Complete Analysis 2026

MURAStock

Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.

Full MURA Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this MURA vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MURA vs SCHDMURA vs JEPIMURA vs OMURA vs KOMURA vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.